How many insider trades does FilingIQ track for HROW?

FilingIQ tracks 163 Form 4 insider transactions for HROW (HARROW, INC.), covering filings from Jan 2, 2019 onwards. 7 of those were filed in the last 90 days.

Are HROW insiders net buyers or net sellers?

Across the full Form 4 history for HROW, 69 transactions (42%) were open-market purchases and 34 (21%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does HROW insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is HROW in?

HARROW, INC. (HROW) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $1.32B.

HROW insider trading

NasdaqGM Healthcare

HARROW, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

163

Last 90 days

Buys / sells

42% / 21%

Market cap

$1.32B

About HARROW, INC.

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.

Company website: www.harrow.com

HROW insider activity at a glance

FilingIQ has scored 163 insider transactions for HROW since Jan 2, 2019. The most recent filing in our index is dated May 14, 2026.

Across the full history, 69 open-market purchases and 34 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on HROW insider trades is 52.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live HROW trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding HROW

Opaleye Management Inc.

$191.34M · 25.2% of AUM

EAM Investors, LLC

$6.56M · 1.3% of AUM

B. Riley Financial, Inc. (RILY, RILYG, RILYK, RILYL, RILYM, RILYN, RILYP, RILYT, RILYZ)

$2.30M · 0.5% of AUM

Frequently asked

How many insider trades does FilingIQ track for HROW?: FilingIQ tracks 163 Form 4 insider transactions for HROW (HARROW, INC.), covering filings from Jan 2, 2019 onwards. 7 of those were filed in the last 90 days.
Are HROW insiders net buyers or net sellers?: Across the full Form 4 history for HROW, 69 transactions (42%) were open-market purchases and 34 (21%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does HROW insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is HROW in?: HARROW, INC. (HROW) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $1.32B.

Methodology & sources

Every HROW insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.